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A
Acetylcholine metabolism, brain synaptosomes, CRF.... 630
Acidification, renal capacity, lithiasis (abst) 1418
Acidity, titratable, urinary stone risk factors 120
Acidosis, metabolic, growth factor expression 1224
Acquired cystic kidney disease
hemodialysis (abst) 1412
transplantation, CsA and 613
Acute pancreatitis, post-transplant (abst) 1425
Acute phase reactans C3a, /3-m, HD (abst) 1437
Acute renal failure
African honey bee (abst) 1455
Bolivia (abst) 1436
bone marrow transplantation (abst) 1477
cholera, renal injury (abst) 1420
clinical analysis (abst) 1452
CsA, liver transplantation (abst) 254
diagnosis/management, computer systems (abst) 907
EPO deficit, anemia (abst) 1411
gene expression as recovery markers (abst) 1178
immunoallergic, children, NSAIDs (abst) 467
liver transplantation (abst) 1499
Malarie Falciparum (abst) 1455
mortality rates (abst) 1430
neuroleptic malignity syndrome (abst) 907
obstetrics (abst) 1441
oliguric, furosemide (abst) 1451
post-cardiovascular surgery, CAVH (abst) 1416
pregnancy (abst) 1431
renal artery embolism (abst) 1462, 1480
sepsis and (abst) 1430
septic abortion (abst) 1424
treatment, Cuba (abst) 1493
Acute vascular rejection, OKT3 (abst) 1416
Addison's disease
glucocorticoids, panhypopituitarism 1130
glucocorticoids, panhypopituitarism (abst) 1196
Adenosine
K channels, ANF, Ang II glomerular responses
(abst) 240
medullary TAL as source (abst) 239
Adhesion molecules
human kidney 147
PMMA dialysis membrane (abst) 1394
renal inflammation 42:S-27
Adolescents, hypertension, BP monitoring (abst) 1477
Adrenal masses, hypertension (abst) 1473
Adrenal microadenomas, hypertension, aldosterone
(abst) 916
Adrenalectomy, protein, enzyme activity (abst) 263
Adult polycystic kidney disease, epidemiology (abst) . . . 1424
African honey bee, ARF (abst) 1455
Albumin
excretion, oral protein load (abst) 907
as HD mortality predictor 115
Aldosterone
adrenal microadenomas, hypertension, renin (abst). . . . 916
modulates PNA-labeled cells, CD epithelium 537
Alkalosis, proximal tubule/TAL adaptation (abst) 1463
Allergic reactions
HD (abst) 1414
incidence, HD (abst) 1422
Allografts
children, glomerulopathy 43:S-95
children, growth hormone treatment 199
children, recurrent disease in 43:S-91
CMV-seropositive, immunoprophylaxis (abst) 266
creatinine clearance as GFR marker, CsA (abst) 255
donor related non-Hodgkin lymphoma (abst) 466
flow cytometric cross match, antibody status (abst)... 1393
ULA matching, effect on graft survival (abst) 1190
impairment, cyclosporine triple therapy (abst) 1425
malignancy in recipients (abst) 1191
pneumocystis carini pneumonia, prevalence (abst) .... 264
rejection, Banif classification 411
rejection, children, T cell signaling role 43:S-3
rejection, detection by dopplersonography (abst) 256
rejection, embolization with ethanol (abst) 1468
rejection, glycolipid blood group antigens 1289
rejection, HLA-identical recipients (abst) 468
rejection, intrarenal CsA deposits (abst) 1402
rejection, OKT3 therapy (abst) 468, 1416
rejection, serum hippuric acid (abst) 261
rejection, tissue specific recognition (abst) 1193
rejection, VCAM-l expression 805
rupture, cyclosporine (abst) 1471
specific glomerular lesion 42:S-104
steroids, azathioprine, CsA (abst) 1443
survival, cyclosporine, cadaver grafts (abst) 1418
a-interferon therapy, HBV-associated GN (abst) 1184
Alport syndrome
COL4AS gene analysis (abst) 250
COL4A5 mRNA variant splicing 1316
COL4A5 probe, phenotype correlation (abst) 1183
COL4AS single base insertion 1091
multicenter study, Italy (abst) 1399
Aluminum
adynamic IDDM, non-diabetic uremia (abst) 1445
bone cells, cytokines (abst) 1498
bone metabolism, normal renal function (abst) 1498
bone stores, measurement (abst) 1498
deferoxamine test dosage (abst) 1458
removal, desferroxamine therapy (abst) 1497
Aluminum absorption
citrate, RF (abst) 253
erythrocytic dysmorphism, HD, uremia (abst) 1400
erythropoiesis, rats (abst) 1463
erythropoiesis, renal failure (abst) 1463
hemoperfusion, HD, desferioxamine (abst) 910
Aluminum hydroxide
hyperphosphatemia, calcium acetate therapy (abst).... 260
plasma, bone aluminum concentration, uremia (abst) . 1464
Aluminum toxicity
iron absorption, EPO therapy, anemia, HD (abst)... . 1467
osteodystrophy, "suppressed" PTH 860
role in immunosuppression (abst) 1453
1546
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treatment (abst) 1498
Ambulatory blood pressure monitoring (ABPM)
arterial hypertension, adolescents (abst) 1477
arterial hypertension (abst) 1481
hypertension, HD (abst) 1444
white coat" hypertension (abst) 1444
Amino acids
cognitive function, HD (abst) 908
intra-arterial infusion, GFR, glucagon (abst) 1413
profiles, CAPD (abst) 1188
supplementation, muscle metabolism (abst) 465
Amyloid arthropathy, C-reactive protein levels (abst)... 1395
Amyloid deposits, proteinase inhibitors (abst) 1409
Amyloidosis
f32-m synthesis, HD, lymphokines (abst) 1409
dialysis-related (abst) 1461
nephrotic syndrome (abst) 1183
primary, survival factors (abst) 1408
renal (abst) 1431
uremia, IL-2R serumlsynoviai fluid levels (abst) 1395
AN69 membranes, anaphylactoid reactions (abst) 1481
Analbuminemia, ovariectomy, triglycerides (abst) 1193
Analgesic nephropathy 42:S-86
Anaphytactoid reactions, AN69 membranes (abst) 1481
Anemia
ARF, endogenous EPO deficit (abst) 1411
EPO therapy, aluminum intoxication (abst) 1467
EPO therapy, CAPD, HD (abst) 1479
EPO therapy, CRF, children (abst) 911
EPO therapy, uremia, not on dialysis (abst) 1434
EPO therapy (abst) 912
EPO with intravenous iron, HD (abst) 911
post-transplant (abst) 1423
rHuEPO therapy, cardiovascular aspects 1309
rHuEPO therapy, chronic rejection (abst) 470
rHuEPO therapy, estimating Hb/Hct (abst) 1441
rHuEPO therapy, pre-dialysis (abst) 1475
therapy, brain cell function (abst) 911
zinc levels, CRF, HD (abst) 1484
Anergy, CD4 T cell, tubular epithelial cells 1030
Angiotensin-( 1-7), phospholipase, Na transport 932
Angiotensin converting enzyme (ACE)
hemodialysis (abst) 1437
hypertension, diuretics (abst) 1420
hypertension, immunosuppression (abst) 1439
renovascular hypertension, Ang II receptors (abst).... 245
renovascular hypertension (abst) 245
Angiotensin converting enzyme (ACE) inhibition
antihypertensive agents, Ca antagonist, OS (abst).... 1178
antiproteinuric effect, renal hemodynamics (abst) .... 1195
bradykinin, efferent arteriolar dilation 545
brain ANF, rats (abst) 246
brain ANF, renal insufficiency 24
HBV, glomerulonephritis (abst) 1184
hemodynamics, proteinuria 579
renal hippuran extraction, rats (abst) 1194
renovascular hypertension, Nephrology Forum 1379
Angiotensin II
ANF, adenosine glomerular responses (abst) 240
AVP, MC expression (abst) 242
catecholamines, low-protein diet 285
elevation, polydipsia, HD 107
mesangial response, glucose, ANP 518
Angiotensin 11 receptors
localization, rat kidney 42:S-40
regulation, ADPKD (abst) 243
renovascular hypertension (abst) 245
streptozotocin-induced DM, rats (abst) 1392
Angiotensin inhibitors, nephrotic syndrome (abst) 1415
Angiotensin type-i receptor mRNA, expression, rats.... 331
Anion exchange, protein identified in proximal tubule .. . 565
Anti-CD3 monoclonal antibodies (abst) 1198
Anti-DNA monoclonal antibodies (abst) 905
Anti-glomerular basement membrane nephntis
crescentic, urine urokinase activity (abst) 1181
glomerular expression TGF-13, PDGF (abst) 905
glomerular fibnnolytic activity 557
HLA-DR and -DQ types 307
Anti-N-like antibodies, clinical significance (abst) 1407
Anti-neutrophil cytopiasmic antibodies (ANCA)
diagnostic significance of detection (abst) 906
renal perfusion of proteinase 3 (abst) 1194
Anti-thymocyte antiserum, ON, MCP-l expression 1036
Antibiotic therapy, endocarditis, ON (abst) 469
Antibody status, flow cytometric cross match (abst).. . . 1393
Anticoagulant factor protein S, membranous ON (abst) . 1398
Anticoagulants, prophylactic use, nephrosis (abst) 265
Antidiuretic hormone, antagonist OPC-3l260, SIADH .... 19
Antigens
expression, rejected ABO incompatible grafts 1289
presentation by parenchymal cells 927
Antihypertensive agents
ACEi, Ca antagonist, glomerulosclerosis (abst) 1178
isolated systolic hypertension, renal function (abst).. .. 911
long-acting (abst) 908
LVH regression, uremia, HD 881
Antilymphocytic globulins
delayed graft function (abst) 913
lymphocytic molecules, rosette phenomenon (abst).... 465
monoclonal gammopathy, post-transplant (abst) 265
Antimicrobial prophylaxis, recurrent UTI (abst) 1434
Antineutrophil cytoplasmic autoantibodies (ANCA)
glomerulonephritis (abst) 1184
lupus nephritis 1185
oculo-renal syndrome (abst) 1431
steroids, renal vasculitides 215
transplantation, polyarteritis (abst) 469
vasculitis prevalence, dialysis (abst) 252
Antisense oligonucleotides, IL2R gene expression (abst)... 255
Aplastic osteodystrophy, aluminum, "suppressed" PTH... 860
Apolipoproteins
epitopes of LDL, HD 1360
lipoprotein(a), diabetics, HD (abst) 908
phenotypes, HD, with/without DM 1062
ratio in uremia, fibric acid, clinofibrate 1352
Area under the curve, prevents CsA toxicity 436
Arginine synthesis, chronic renal failure 676
Arginine vasopressin (AVP)
Ang II, MC expression immediate early genes (abst)... 242
collecting tubule action, changes in pH 1235
extracellular Na, [Ca2'11 increase 755
Arterial pressure
changes and metal ions (abst) 908
EPO therapy (abst) 1482, 1490
Arteriovenous fistula
autoexpanded metallic endovascular prosthesis (abst). 1491
biopolymeric prosthesis, HD (abst) 1491
coagulation inhibitor deficiency (abst) 469
color Doppler ultrasonography (abst) 1470
femoral, HD (abst) 470
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opening/closing, hemodynamics, HD (abst) 1465
Aspiration-sclerotherapy, renal cysts (abst) 1177
Atenolol, renal function, diabetic nephropathy (abst) ... 1197
ATG-Fresenius prophylaxis with OKT3 (abst) 266
ATP, cellular mechanisms, calcium activity (abst) 241
ATP analogues, UTP, phospholipase (abst) 258
ATP-ase dependent Na/K pump, liquorice abuse (abst) . 1400
Atrial natriuretic factor (ANF)
ACE inhibitors, rats 24
ACE inhibitors, rats (abst) 246
Ang II, adenosine glomerular responses (abst) 240
biologic/physical characteristics 937
CAPD (abst) 1465
Atrial natriuretic peptide (ANP)
BP response, high salt intake (abst) 246
insulin, CRF (abst) 910
mesangial response, glucose, Ang II 518
Na, water transport, rat CCD 30
natriuretic action (abst) 472
streptozotocin-induced DM (abst) 471




alloimmunized patient, SLE, anemia (abst) 469
Autosomal dominant polycystic kidney disease (ADPKD)
Ang II receptors (abst) 243
clinical management 42:S-74
clinical study, Toronto 1101
clinical survey, gene carriers (abst) 1425
clinical utility of genetic markers (abst) 1405
glycoprotein expression, ECM (abst) 243
immunohistochemical detection of renin (abst) 243
morphology/immunocytochemistry, rats (abst) 243
polymorphism of PGP for diagnosis (abst) 244
Azathioprine
after triple therapy (abst) 255
cyclosporine, outcome (abst) 1481
cyclosporine triple therapy, graft function (abst) 1425
hypersensitivity (abst) 261
leukopenia, GM-CSF, post-transplant (abst) 1191
steroids, CsA double therapy (abst) 1443
steroids, hepatitis B reactivation (abst) 1427
Aztreonam-cloxacillin, UTI prophylaxis (abst) 1440
B
B7/CD28 pathway in dialysis patients 359
Bacteremia
chronic HD, multicenter study (abst) 467
enterococcus, endocar(Jitis (abst) 1418
in renal failure (abst) 1470
Bacterial endocarditis, antibiotic therapy (abst) 469
Banff classification, transplant pathology 411
Bartter/Gitelman syndrome (abst) 1197
Bartter's syndrome 401
Benzbromarone, uricosuric efficacy of (abst) 267
Benziodarone, hyperuncemia, transplantation (abst).... 1480
Berger's disease, clinical histology (abst) 1403
fl-glycosylated erythropoietin
cell mediated immunity, HD (abst) 912
platelet aggregation, HD (abst) 912
I3 integrins, membranous nephropathy (abst) 1392
f2 microglobulin
acute phase reactans C3a, HD (abst) 1437
amyloid deposits, plasma proteinase inhibitors (abst) . 1409
granulocyte inhibitory protein isolated, HD (abst) 253
HD, amyloidosis, lymphokines (abst) 1409
IL-I, TNF release (abst) 1472
11 -/3OHSD, prednisolone/prednisone ratio (abst) 263
Bicarbonate dialysate
COPD ventilatory function on HD (abst) 1462
PD, buffer, biocompatibility (abst) 1394
Biopolymeric prosthesis, HD (abst) 1491
Biopsy
bone marrow, familial Mediterranean fever 834
renal, follow-up (abst) 1181
renal, FSGS, minimal change disease (abst) 905
renal, interstitial nephritis (abst) 1179
renal, lupus nephropathy (abst) 1406
renal, systemic vasculitis (abst) 1429
renal percutaneous (abst) 1416, 1420, 1458
Blood pressure
arterial, isradipine, renal hemodynamics (abst) 1429
chronic HD patients, EPO therapy (abst) 1413
lisinopril, microalbuminuria, proteinuria (abst) 1407
nocturnal changes, cerebral ischemia (abst) 246
post-high sodium intake, ANP (abst) 246
Blood transfusions, autologous, EPO therapy (abst) 469
Blood volume monitoring, non-invasive, dry weight, HD... 851
Body composition
altered, post-transplant, CsA (abst) 261
altered, post-transplant, glucocorticoids (abst) 261
CRF, HD (abst) 1449
ESRD, dialysis modality (abst) 261
Body mass index (BMI)
cardiovascular morbidity, hypertension (abst) 1453
obesity, essential hypertension, CV risk (abst) 1419





children, hypercalciuna (abst) 1176
children, hypercalciuric/normal (abst) 1421
chronic HD, hyperparathyroidism (abst) 253
idiopathic calcium stone formers (abst) 264
post-transplant (abst) 267
transplantation, HD (abst) 1457
transplantation, post-PD (abst) 1449
Bone histology, PTH, vitamin D3, radiology, ESRD.... 1071
Bone histomorphometric pattern, IDDM (abst) 1445
Bone marrow
biopsy, familial Mediterranean fever 834
changes, post-EPO therapy, HD (abst) 1185
transplantation, risk factors, ARF (abst) 1477
Bone metabolism
aluminum (abst) 1498
serum procollagen type-I, HD (abst) 909
Bradykinin
during ACE inhibition 545
Na, water transport, rat CCD 30
Brain cell function, renal anemia, CAPD (abst) 911
Brain death, diagnosis, transcranial Doppler (abst) 1459
Brain natriuretic peptide (BNP) 937
Brain synaptosomes, acetylcholine metabolism 630
C
Cadaver renal grafts
long-term renal function (abst) 1439
retransplantation (abst) 1473
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survival rates, cyclosponne (abst) 1418
survival rates, Hispanoamerica (abst) 1405
Third World, Hispanoamerica, Cuba (abst) 1420
utilization in children 43:S-99
Cadmium exposure
renal dysfunction (abst) 250
renal tubular acidosis (abst) 1176
Calbindin-D28k, gene expression, murine kidney 322
Calcitonin, PTH, calcium stone formers (abst) 1397
22-oxa-calcitriol
PTH secretion, Ca transport, CRF (abst) 467
secondary hyperparathyroidism, calcium metabolism .. 551
Calcitriol
extrarenal synthesis, uremia 134
PTH, 22-OXA-1,25D, Ca transport, CRF (abst) 467
Calcitriol therapy
chronic HD (abst) 1455
hyperparathyroidism, chronic HD (abst) 1408
immunological effects, HD, uremia (abst) 1398
intravenous, post-dialysis bolus (abst) 1468
1,25(OH)2D3, PTH, CAPD (abst) 1399
osteocalcin levels, chronic HD (abst) 1408
renal osteodystrophy, CRF (abst) 909
risks/benefits, chronic HD (abst) 259
severe HPT (abst) 253Ca + ions, arterial pressure changes (abst) 908
[Ca2], increase, AVP-induced, extracellular Na 755
Calcium2 uptake, glucose elevation, VSMC 344
Calcium
22-oxa-calcitriol, hyperparathyroidism 551
cell volume, pH, RAS oncogene expression (abst) .... 241
iron, oxidant-induced DNA damage 1228
kinesis, renal osteodystrophy (abst) 909
quantification, VS MC, hypertension (abst) 244
signaling, MC, protein kinase C (abst) 1397
transport, PTH, calcitriol, 22-OXA-1,25D, CRF
(abst) 467
urinary creatinine, children (abst) 1176
Calcium acetate, aluminum hydroxide therapy (abst) .. . . 260
Calcium antagonists
ACEi, antihypertensive agents, OS (abst) 1178
ACEi, hypertension, immunosuppression (abst) 1439
cyclosporin A therapy, post-transplant (abst) 1496
renal graft function (abst) 913
Calcium channels
intracellular Ca in VSMC, rats (abst) 1393
mesangial cells (abst) 241
Calcium oxalate crystals
epitaxial growth, CaCO3 crystals (abst) 472
modified, Tamm-Horsfall protein, citrate (abst) 263
Calcium-phosphate metabolism
histomorphometric bone pattern (abst) 1445
Calcium renal stones
hypercalciuria, PTH, calcitonin (abst) 1397
hypocitraturia, without calculi (abst) 1442
urinary citrate relative to calcium (abst) 1442
Calcium salts, calcium dialysate (abst) 265
Caloric malnutrition, protein catabolic rate (abst) 1467
cAMP- and dopamine-dependent phosphoprotein
(DARPP-32) 495
Candida peritonitis, PD (abst) 1452
Captopril
diagnosis, renovascular hypertension (abst) 1448
inhibits metalloproteinases 1266
renal function, diabetic nephropathy (abst) 1197
scintigraphy, renal artery stenosis (abst) 1495
Carbohydrate metabolism
body composition, CsA, lipids (abst) 261
nifedipine, CRF (abst) 1455
vitamin B6, CRF (abst) 1456
Carcinoma
renal cell, cytokine expression 585
renal cell, Von Hippel-Lindau syndrome (abst) 250
Cardiac function, systolic/diastolic, dialysis (abst) 1499
Cardiac gated blood pool scan, ESRD (abst) 1186
Cardiovascular aspects of rHuEPO therapy 1309
Cardiovascular complications
EPO therapy, HD (abst) 1470
post-transplant (abst) 1464
Cardiovascular disease
morbidity, hypertension, BMI (abst) 1453
risks in cyclosporine therapy (abst) 1424
risks in essential hypertension, obesity (abst) 1419
Cardiovascular surgery, ARF, CAVH (abst) 1416
Carnitine losses, HD (abst) 1494
Cascade lipidapheresis, hypercholesterolemia (abst) 916




exit-site infection (abst) 915
malfunction, nonoperative repair (abst) 1189
migration (abst) 1477
post-operative complications (abst) 919
Swan neck (abst) 1472
CD4 T cell anergy, tubular epithelial cells 1030
Ceftriaxone-cloxacillin, UT! prophylaxis (abst) 1440
Cell adhesion molecules
expression, human kidney 147
leukocyte-endothelial, renal inflammation 42:S-27
renal inflammation 42:S-27
vascular, allograft rejection 805
Cell depolarization, inhibition of K channels (abst) 237
Cell mediated immunity, EPO, HD (abst) 912
Cell mediated lympholysis, post-transplant (abst) 1427
Cell proliferation, RAS oncogene expression (abst) 241
Cellulose triacetate dialyzer (abst) 1494
Central nervous system, magnetoencephalography
(abst) 914
Cerebral hemorrhage, risk factors, dialysis 1086
Cerebral ischemia, nocturnal BP changes (abst) 246
Cerebrovascular complications, post-transplant (abst)... 1464
cGMP inhibits Cl flux n the mTAL 741
Chagas disease, transmission (abst) 1461, 1462
Children
acute rejection, steroids, OKT3 therapy (abst) 1454
allograft glomerulopathy 43: S-95
bone density, hypercalciuria (abst) 1176
CRF, anemia, EPO therapy (abst) 911
CRF. growth hormone therapy (abst) 1185
CRF, hyperparathyroidism (abst) 1417
CRF, protein diet (abst) 1417
focal segmental glomerulosclerosis (abst) 1426
OFR determination methods (abst) 1409
growth hormone therapy, allografts 199
hypercalciuria, bone mineral content (abst) 1421
hypertension (abst) 1407
immunoallergic ARF, NSAIDs (abst) 467
maintenance dialysis 43:S-l04
nephrotic syndrome, CsA toxicity (abst) 1182
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nephrotic syndrome, cyclosporin (abst) 906
nephrotic syndrome, FSGS (abst) 1182
nephrotic syndrome, interleukin (abst) 1182
OPD nephrology clinic (abst) 1435
peritoneal kinetics, CAPD (abst) 1457
post-transplant hospitalization 43:S-83
rHuEPO therapy, anemia, CRF (abst) 1411
rHuEPO therapy, pre-dialysis (abst) 1402
transplantation, ages one to five years 43:S-40
transplantation, cadaver grafts 43:S-99
transplantation, cyclosporine dosing 43:S-50
transplantation, five-year survival 43:S-16, 43:S-22
transplantation, growth, long-term follow-up 43:S-56
transplantation, growth hormone therapy. 43:S-62, 43:S-65,
43:S-71, 43:S-76
transplantation, growth suppression, steroids 43:S-59
transplantation, immunizations 43 :S-87
transplantation, recurrent disease 43:S-91
transplantation, steroid resistant NS (abst) 256
transplantation (abst) 1435
urinary calcium/creatinine ratios (abst) 1176
urolithiasis, metabolic study (abst) 1414
urolithiasis (abst) 1455
Chloride removal and AVP action 1235
Cholera
ARF, measuring renal injury (abst) 1420
IRA complications (abst) 1410
Cholesterol metabolism
hepatic, puromycin-induced NS, rats 789
LDL uptake, mesangial cells (abst) 248
lovastatin, lipid glomerulopathy (abst) 249
Cholesteryl ester transfer protein, proteinuria, LCAT .... 91
Cholinesterase, tubular enzymuria, diabetics (abst) 1396
Chondrocalcinosis, renal pathophysiology (abst) 1197
Chondrocytes, intermittent/continuous 1 ,25(OH)2D3 708
Chronic obstructive lung disease, HD (abst) 1462
Chronic renal failure
1 ,25(OH)2D3, cellular immune response (abst) 1403
acetylcholine metabolism, brain synaptosomes 630
atrial natriuretic peptide, insulin (abst) 910
blood glutathione, RBC antioxidation (abst) 1186
body composition, HD (abst) 1449
calcitriol therapy, renal osteodystrophy (abst) 909
carbohydrate metabolism, nifedipine (abst) 1455
carbohydrate metabolism, vitamin B6 (abst) 1456
care program, Chile (abst) 1424
children, EPO therapy, anemia (abst) 911
children, GFR determination (abst) 1409
children, growth effect of rhGH (abst) 1185
children, hyperparathyroidism (abst) 1417
children, protein diet (abst) 1417
creatinine clearance as GFR marker 1145
dyslipidemia, lipoprotein(a), HD (abst) 1187
free/protein-bound tryptophan 1366
GTT, insulin, blood sugar, GH (abst) 1456
HD, survival rate/causes of death (abst) 1186
insulin and hypertension (abst) 910
lipoprotein(a), post-transplant (abst) 1190
mild, cytosolic free sodium (abst) 253
morbidity, Cuba (abst) 1456
morbidity, elderly (abst) 1456
muscle glycogen, glycolytic activity (abst) 1393
parathyroid hormone, dietary protein 173
plasma endothelin (abst) 916
pregnancy (abst) 466, 1469
prevalence, population study (abst) 1457
progression, evaluation methods (abst) 1460
PTH, calcitriol, 22-OXA-l,25D, Ca transport (abst) ... 467
renal arginine synthesis 676
rHuEPO effects on Q-EEG, event related potentials.. 1109
rHuEPO therapy, anemia, children (abst) 1411
risk factors, population study (abst) 1456
slow progression, uric acid, serum phosphorus (abst) . 1436
spontaneous decrease PMN cells, HD (abst) 1450
Cimetidine, creatinine clearance, GFR (abst) 1434
Cisplatin nephrotoxicity, thyroxine (abst) 1178
Cisplatinum, urinary excretion (abst) 251
Citrate
aluminum absorption, RF (abst) 253
calcium, Tamm-Horsfall protein, COM crystals
(abst) 263
urinary excretion, calcium stone formers (abst) 1442
Clinofibrate, APO ratio, uremia, fibric acid 1352
Clonidine, Na, water transport, rat CCD 30
Clorambucil, prednisone, membranous GN (abst) 1437
Cloxacillin, UT! prophylaxis (abst) 1440
Coagulation inhibitor, AV fistula clotting (abst) 469
Cognitive function, amino acids, HD (abst) 908
COL4A5
gene analysis, Alport syndrome (abst) 250
mRNA variant splicing, Alport syndrome 1316
probe, Alport syndrome (abst) 1183
single base insertion, Alport syndrome 1091
Collagen type III
expression, in vitro model (abst) 1392
glomerulopathy (abst) 250
Collagenase type IV, release from MC, activation
(abst) 242
Complement CIQ component, IgG binding, MC (abst).. 1192
Complement C4 biosynthesis, IFN-y stimulation 50
Complement deficiency
IgA-mediated glomerular inflammation (abst) 1192
nephritis, vasculitis 42:S-l3
Computer systems
diagnosis/management, ARF (abst) 907
dialysis prescription (abst) 1490
donor-recipient selection process (abst) 1490
transplantation (abst) 1491
Congenital nephrotic syndrome, Finnish type 867
Congestive heart failure, ibopamine, hemodynamics
(abst) 1196
Continuous ambulatory peritoneal dialysis (CAPD)
adequacy, membrane permeability (abst) 1399
arterial pressure, peritoneal clearances (abst) 1394
atrial natriuretic factor 1465
bone densitometry (abst) 1478
brain cell function, renal anemia (abst) 911
catheter malfunction (abst) 1189
catheter migration (abst) 1466
catheter (swan neck) insertion (abst) 1403
catheter (Tenckhofl) (abst) 919
catheter (TWH), complications (abst) 919
children, mineral metabolism (abst) 1465
children, peritoneal kinetics (abst) 1457
CNS function analysis with MEG (abst) 914
diabetic nephropathy (abst) 1449
dietary protein intake equations 1048
exit site/subcutaneous tunnel infections (abst) 915
HCV prevalence (abst) 1188
HI V-infected patients, outcome 191, 373
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hydrostatic-induced transport during 1078
IgG concentration in dialysate (abst) 1412
KT/V index, clinical outcome (abst) 1188
lymphocyte subsets (abst) 1476
membrane plasmapheresis, leptospirosis (abst) 1452
metabolism, peritoneal equilibration test (abst) 915
metabolism, platelet prostanoids (abst) 914
multifocal accumulation (abst) 1189
nutritional status, assessment (abst) 1412
nutritional status, peritoneal transport (abst) 1458
nutritional status (abst) 1458
1,25(OH)2D3, PTH, calcitriol therapy (abst) 1399
peritonitis, epidemiology (abst) 914
peritonitis, foreign body ileal perforation (abst) 264
peritonitis, fungal (abst) 1189
peritonitis, gram-negative (abst) 1189
peritonitis, inflammatory indicators (abst) 1197
peritonitis, intra-peritoneal free elastase 87
peritonitis (abst) 919
plasma, RBC amino acid profiles (abst) 1188
prescription, new method (abst) 1442
protein catabolic rate adequacy tests (abst) 464
renal osteodystrophy (abst) 910
selection criteria (abst) 1427
ultrafiltration loss (abst) 914
urea kinetic modeling (abst) 260
water transport model 700
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Perinatal deaths, urinary tract anomalies (abst) 1176
Peripheral blood mononuclear cells (PBMC)
cytokine networks, IgA nephropathy 1298
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estimation by delta of volume (abst) 1417
protein/caloric malnutrition, HD (abst) 1467
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uremic, serological markers, HD (abst) 1467
Psychogenic water intoxication, complications (abst) .. . . 471
Pulmonary function, changes with EPO therapy (abst).. 1469
Puromycin nephropathy
exacerbated by rhGH, rats 1281
hepatic cholesterol metabolism, rats 789
Q
Quantitative electroencephalography (Q-EEG) 1109
R
Radiation nephritis, renal protection (abst) 1421
Radiologic studies, bone histology 1071
RANTES and mesangial cells 795
Rapamycin inhibits TNF-a production, PTEC 352
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intrarenal pressure, post-transplant (abst) 1421
neonatal heat stress (abst) 1179
pretranscriptionally IL-6 production (abst) 254
progression, additional renin gent, rat (abst) 244
tetanus, rhabdomyolysis (abst) 1426
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haploidentical patients (abst) 1435
HBV reactivation, immunosuppression (abst) 1427
HCV and CMV antibodies, HD (abst) 1430
HCV prevalence (abst) 914
HLA-identical recipients, OKT3 (abst) 468
hypertension management 43:S-45
hyperuricemia, benziodarone (abst) 1480
hypophosphatemia (abst) 1483
IgA, IgG2a anti-CD3 isotype switch variants (abst)... 1198
IL-6 determinations, diagnostic value (abst) 256
immunosuppression, lipid levels (abst) 1198
immunosuppression, prophylactic, OKT3, ATG-F
(abst) 266
infections with triple immunotherapy (abst) 914
infectious disease complications, Nephrology Forum . . 221
influenza vaccination (abst) 918
intrarenal pressure determination (abst) 1421
Kaposi's sarcoma (abst) 918
Latin American program (abst) 1450
leukopenia, treatment (abst) 1479
lipid abnormalities, uremia, HD (abst) 1441
lipid metabolism (abst) 1474
lipoprotein(a) concentration, CRF (abst) 1190
living donors, outcome (abst) 1468
living unrelated donors (abst) 1398
long-term renal function, cadaver donors (abst) 1439
lower gastrointestinal perforations (abst) 913
lymphocele as complication (abst) 918
menstrual function (abst) 913
obstructive uropathy (abst) 1466
organ exchange, HLA matching (abst) 1480
pancreas/kidney, lipid levels (abst) 266
pneumocystis carini pneumonia (abst) 264
Priscilla Kincaid-Smith, contributions of 42:S-99
proteinuria, incidence/cause (abst) 1190
proteinuria, prognostic meaning of (abst) 1423
PTH secretion, urinary phosphate loss (abst) 465
recurrent ON, prognosis (abst) 257
renal functional reserve, RAS 165
respiratory infection (abst) 1422
rHuEPO therapy for chronic rejection (abst) 470
risk factors, retransplantation (abst) 918
screening diabetics for CAD 617
selection criteria (abst) 1432
before starting dialysis (abst) 1440
steroid withdrawal 43:S-30
steroid withdrawal, children 43:S-36
steroid withdrawal, metabolic effects, adults 43:S-26
survival rates, Argentina (abst) 1414
survival rates, non-parametric estimation (abst) 1490
survival rates, Spain (abst) 1480
survival rates, Uruguay (abst) 1422
theophylline, erythrocytosis (abst) 918
tuberculosis, distribution (abst) 1458
urinary fistula after 1463
urinary fistula after (abst) 1494
urinary obstruction after (abst) 1463, 1493
viral pneumonia (abst) 471
Triamterene-thiazide association, renal effects (abst) .... 464
Triglycerides
ovariectomy, GS, analbuminemia (abst) 1193
sodium-lithium countertransport, DM nephropathy.... 127
Tryptophan, free/protein-bound, CRF 1366
Tuberculosis (abst) 1458
Tubular acidosis, induced by cadmium (abst) 1176
Tubular epithelial cells
Ang-(l-7) action, phospholipase A2, Na transport 932
IFN-y-activation, lupus nephritis (abst) 1441
induce CD4 T cell anergy 1030
superantigens, stimulate T cell proliferation (abst) 243
Tubule interstitial disease (abst) 1451
Tubulointerstitial nephritis, chronic 42:S-71
Tumor markers, long-term changes, HD (abst) 917
Tumor necrosis factor-a
expression, renal cell carcinoma 585
HLA-antigens (abst) 1486
IL-6, HD (abst) 1495
IL-6, monocyte production, rejection (abst) 256
IL-6, monocyte release, uremia (abst) 1392
induces RANTES, mouse mesangial cells 795
mRNA expression, rejecting allograft biopsy (abst).... 255
production by proximal tubule EC 352
transplant rejection, in situ hybridization (abst) 468
Tumor necrosis factor (TNF)
induction, dialysis membrane effect (abst) 1187
PBMC production, dialysis membrane effect (abst)... 1187
Typhus, renal dysfunction, uremia (abst) 1179
U
Ultrafiltration
CAPD, peritoneal membrane changes (abst) 914
HD, L-carnitine, vascular refilling (abst) 260
Ultrasonic percutaneous renal biopsy (abst) 1458
Unilateral kidney, hypertension (abst) 1449
Uninephrectomy
acute oral protein load, albumin excretion (abst) 907
remnant kidney injury, dietary protein (abst) 1454
renotropic activity, renal/hepatic roles (abst) 1177
Urea
bounce, dialysis parameters and (abst) 1417
estimation by delta of volume (abst) 1417
percentage reduction, adequacy HD (abst) 1436
Urea clearance
HD, stable/variable sodium dialysate (abst) 264
overestimation in dialysis prescription (abst) 1427
Urea kinetic modeling
adequacy of dialysis (abst) 260, 916
clinical application (abst) 1186
dialysis parameters adjustment (abst) 1417
dialysis time, females/males (abst) 1484
KT/V index (abst) 1188, 1436
Urea kinetics
double lumen catheter, HD (abst) 1443
measured by microdialysis 622
Uremia
continuous intestinal dialysis, mannitol (abst) 1188
diabetes, renal osteodystrophy (abst) 1435
DNA repair 385
EPO therapy, anemia, not on dialysis (abst) 1434
erythrocytic dysmorphism, aluminemia, HD (abst) ... 1400
extrarenal calcitriol synthesis 134
hyperlipidemia, gemfibrozil treatment, HD (abst) 1419
increased Na/H antiport activity, RBC 574
lipid abnormalities transplantation, HD (abst) 1441
LVH, antihypertensive therapy 881
NO, platelet dysfunction, dialysis hypotension 445
non-diabetic, aluminum, adynamic IDDM (abst) 1445
Subject Index: Vol. 44 1567
optimal iPTH levels (abst) 1464
scrub typhus, renal dysfunction (abst) 1179
T cell immunity, l,25(OH)2D3, PTH (abst) 1391
I cell proliferation, PTH-dependent 379
Ureteral obstruction
neonatal, collagen studies 593
regulation of RAS 390




specimen storage for enzymatic assay (abst) 1396
Urinary C5b-9 excretion, membranous nephropathy
(abst) 250
Urinary concentration, perinatal asphyxia (abst) 1457
Urinary enzymes, specimen storage for assay (abst).... 1396
Urinary fistula
post-transplant (abst) 1463, 1494
Urinary obstruction
post-transplant (abst) 1463, 1493
Urinary oxalate, protein intake, glycolate excretion 366
Urinary phosphate loss, PTH, transplantation (abst) 465
Urinary sodiumlcreatinine, nephrolithiasis (abst) 1445
Urinary tract anomalies, perinatal deaths (abst) 1176
Urinary tract infection (UT!)
index of reinfection, prophylaxis and (abst) 1434
prevalence, HD (abst) 1488
prophylaxis, ceftriaxone/aztreonam-cloxacillin (abst). 1440
Urolithiasis
children, metabolic study (abst) 1414
children (abst) 1455
UTP, ATP analogues, phospholipase C (abst) 258
V
Vascular access
AV fistula, femoral (abst) 470
AV fistula, recurrent clotting (abst) 469
double-lumen catheter, permanent, percutaneous
(abst) 259
double-lumen catheter, urea kinetics (abst) 1443
double-lumen catheter (abst) 1414
fistula survival factors, HD (abst) 1187
infection post-stent insertion (abst) 470
prostheses (abst) 1491
stenosis, PTA (abst) 1492
twin femoral catheters (abst) 470
two-year experience (abst) 1452
Vascular cell adhesion molecule- 1 expression 805
Vascular endothelial growth factor, mesangial, PBMC... 959
Vascular smooth muscle cells
calcium channel/intracellular activity, rats (abst) 1393
glucose elevation, calcium ion uptake 344
intracellular calcium pools, hypertension (abst) 244
proliferation, CsA, Na/H-antiport (abst) 254
Vasculitis
ANCA-positive, prevalence, dialysis (abst) 252
pathogenesis, complement deficiency 42:S-13
systemic, renal biopsy findings (abst) 1429
Vasoactive hormones in protein deprivation 285
Ventricular arrhythmias, double-lumen catheter
insertion (abst) 1481
Verapamil
ACEi, hypertension (abst) 1439
nephrotic proteinuria, protein intake (abst) 1469
Vesicoureteric refiux
reflux nephropathy 42:S-80
refiux nephropathy, familial studies (abst) 1410
renal scarring (abst) 1409
Vessel wall properties, non-invasive measurement
(abst) 252
Vitamin B6, carbohydrate metabolism, CRF (abst) 1456
Vitamin D3
bone histology, radiology, PTH, ESRD 1071
long-term therapy (abst) 1452
VLA-3 distribution, membranous nephropathy (abst) ... 1392
Von Hippel-Lindau syndrome (abst) 250
Von Willebrand factor (abst) 1195
w
Water intoxication, complications (abst) 471
Water transport
CAPD 700
Na, clonidine, rat CCD 30
Wegener's granulomatosis
ANCA, microscopic polyarteritis (abst) 469
ANCA, renal perfusion, proteinase 3 (abst) 1194





Zinc levels, anemia, CRF, HD (abst) 1484
